NR3C2 and neoplasm: Ex vivo targeting of MR-bearing macrophages with oxi-mannan-MUC1 followed by adoptive transfer, which is efficient in presenting MUC1 to T cells, results in high-frequency CTL generation and protection against a tumor challenge [203].